Opthea Limited (AU:OPT) has released an update.
Opthea Limited, a clinical-stage biopharmaceutical company, has appointed John Han, PharmD, as their new Vice President of Medical Affairs, bringing over two decades of experience in medical affairs within ophthalmology to the executive team. His extensive background includes significant roles at companies like Regeneron Pharmaceuticals and Adverum Biotechnologies, and he is poised to support the launch of Opthea’s promising new therapy for retinal diseases such as wet AMD. Dr. Han’s expertise will be critical as Opthea advances towards their Phase 3 trial results and prepares for the potential market introduction of their lead product candidate, sozinibercept.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
